安成生物科技 TWi Biotechnology, Inc.

WHAT WE DELIVER

Focused on significant unmet medical needs, leveraging established expertise in rare diseases, dermatology, and CNS disorders

Pipeline

From early-stage research to clinical trials, we drive innovation through data and evidence. Explore our pipeline planning and progress in depth.

Learn More

AC-203

AC-203 reduces the activity and expression of pro-inflammatory cytokines, particularly IL-1β, TNF-α, and TGF-β. It also inhibits the activity of iNOS and the production of nitric oxide.

Learn More

AC-1101

AC-1101 is a patented gel formulation whose active ingredient is a small-molecule Janus kinase (JAK) inhibitor, and it can be used to treat autoimmune inflammatory skin diseases.

Learn More

NORA520

NORA520 which is a prodrug of brexanolone is an innovative therapeutic candidate developed for the treatment of postpartum depression (PPD) and major depressive disorder (MDD).

Learn More

Expanded Access Statement

TWi Biotechnology, Inc. (“TWiB”) is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for patients suffering from diseases with unmet medical needs...

Learn More

WHAT WE DO

Drug Repurposing

We develop innovative therapeutics by repositioning approved drugs for new indications, utilizing novel formulations or prodrug designs through the US FDA’s 505(b)(2) regulatory pathway: New Indications: AC-203, New Formulations: AC-203 , AC-1101, Prodrugs: Nora520.

New drug in development

Partnerships

Geography of Clinical Studies

Learn More about TwiB

WHAT’S NEW

Staying up to date with our latest developments

We keep our stakeholders informed by providing timely updates on our R&D endeavors, clinical trial progress, regulatory milestones, commercial partnerships, financing activities, and corporate actions, etc.

Jun

Press Release．2026

TWi Biotechnology Announces Completion of Primary Endpoint Assessment in Global Phase 2/3 Pivotal Trial of AC-203; Q4 Unblinding Countdown Begins as Company Aims to Deliver the World’s First Treatment for EBS

Jun

Press Release．2026

TWi Biotechnology Initiates Phase 2a Clinical Trial of AC-1101 for Alopecia areata as AC-203 Approaches Key Readout Milestone

Apr

Events．2026

TWi Biotechnology Participates in Taiwan Pharmaceutical Delegation at CPHI Japan with Support from the Industrial Technology Research Institute (ITRI)

Apr

Press Release．2026

TWi Biotechnology Announces Collaboration with EB House Austria to Explore AC-203 for the Treatment of Dystrophic Epidermolysis Bullosa

What are you looking for today?

Quick Links

ESG

From environmental protection and social care to transparent governance, we practice responsible management to create shared prosperity for business and society.

Investors

We continue to deliver on expectations through evidence-based results, sustainable development, and transparent governance. We invite you to join us in witnessing our growing impact.

Working at TWiB

Join us at the forefront of drug development, clinical advancement, and global collaboration—and help create impact that truly matters to society.